Unless otherwise noted, speakers have nothing to disclose.

Moderators

Alper Toker, MD
Boris Sepesi, MD

Presentations

1. Early results and outcomes from NADIM 2 Trial
   Presenter: Nuria M. Novoa, MD, PhD, FEBTS
2. Outcomes of salvage surgery for locally advanced lung cancer after Immunotherapy
   Presenter: Daniel J. Boffa, MD
   Disclosure: Epic Sciences: ran assays for free (Status: Terminated January 2021), Research Grant or Support (Status: Terminated January 2021)
3. Prediction of response to treatment with immunotherapy before surgery. What should a surgeon expect from lymph nodes and margins
   Presenter: Jonathan David Spicer, MD, PhD, FRCSC
   Disclosure: Amgen Inc.: Advisory Board (Status: Terminated); AstraZeneca: Advisory Board, Consultant, Research Grant or Support; BMS: Advisory Board, Consultant; Chemocentryx: Advisory Board, Consultant; CLS Therapeutics: Research Grant or Support; Merck: Advisory Board, Consultant, Research Grant or Support; Novartis: Advisory Board; Protalix Biotherapeutics: Advisory Board, Consultant; Roche Genentech: Advisory Board, Consultant, Research Grant or Support
4. Immunotherapy after surgery in Stage IB to IIIA patients
   Presenter: Isabelle Opitz, MD
   Disclosure: AstraZeneca: Advisory Board, Speaker's Bureau (Status: Terminated June 2021); Medtronic: Research Grant or Support; MSD: Advisory Board; Roche: Research Grant or Support, Speaker's Bureau (Status: Terminated June 2021)
5. Panel Discussion